**Table, Supplemental Digital Content 2:**

Analysis of ATI versus same time-point clinical and biomarker activity status

|  |  |  |  |
| --- | --- | --- | --- |
|  | Disease status | Median ATI µg/ml (IQR) | P value |
| Maintenance ATI | Clinical Remission | 1.00 (0.9-1.1) | **0.03** |
| Clinically active disease | 1.12 (1.02-1.3) |
| Normal CRP | 1.0 (0.9-1.1) | 0.12 |
| Elevated CRP | 1.1 (1.0-1.3) |
| ATI throughout therapy \* | Clinical Remission | 0.9 (0.9-1.1) | **0.04** |
| Clinically active disease | 1.12 (1.01-1.3) |
| Normal CRP | 1.01 (0.9-1.12) | 0.16 |
| Elevated CRP | 1.12 (1.0-1.3) |

\* Throughout therapy - both during induction and maintenance

ATI – Antibodies to Infliximab, CRP – C-reactive protein